Prodia Diagnostic Line Tbk vs Trimegah Karya Pratama Tbk. — how do they compare? Prodia Diagnostic Line Tbk trades at Rp262 (market cap 470.58B, 3.65M 24h volume), while Trimegah Karya Pratama Tbk. trades at Rp145 (market cap 292.02B, 613.5K 24h volume). The key difference: Prodia Diagnostic Line Tbk is the larger of the two by market cap, and Prodia Diagnostic Line Tbk is more actively traded (3.65M versus 613.5K). Which is the better fit depends on your goals.
| PRDL | UVCR | |
|---|---|---|
Market Cap | 470.58B | 292.02B |
Volume | 3.65M | 613.5K |
Lot | 36.49K | 6.14K |
Turnover | 963.03M | 88.84M |
Average Price | 263.89 | 144.81 |
Value | 963.03M | 88.84M |
Indicative Equilibrium Price | 272 | 146 |
Indicative Equilibrium Volume | 418 | 117.3K |
Trailing returns across standard periods
Latest headlines on both assets
PT Prodia Diagnostic Line Tbk (the Company) was established April 16, 2010 with the name of PT DiaLine Systems Indonesia based on Notarial Deed No. 22 of Rismalena Kasri, S.H. On April 25, 2011, PT DiaLine Systems Indonesia changed the Companys name to PT Prodia Diagnostic Line based on Notarial Deed No. 14 of Rismalena Kasri, S.H. The Company is in the form of a Limited Liability Company in 2010 and began commercial production in 2011. The production results are marketed locally. The parent and ultimate parent entity of the Company is PT Prodia Utama.
Read more on PRDL →PT Trimegah Karya Pratama Tbk (the Company) was established based on Notarial Deed No. 21 dated July 7, 2017 of Netty Maria Machdar, S.H. The Company started its commercial operations in 2018. The Company’s immediate parent company is PT Trimegah Sumber Mas, which was established and domiciled in Indonesia, while its ultimate Parent Company is PT Hutama Mulia Rajawali, which was established and domiciled in Indonesia.
Read more on UVCR →